In a move that rivals
Johnson & Johnson 's (NYSE: JNJ) decision
to sue the Red Cross in the quest for the
Maybe-There's-a-Better-Way-to-Solve-This Award, Republicans
this week decided to pick on the beloved AARP.
No matter which side of the
health-care debateyou fall on, it's easy to see that
Republicans are going to have a tough time coming out of this
fight looking like the good guys, even if they are right.
What's in a name?
For a nonprofit with a well-recognized name like AARP,
about $650 million. That's the amount the nonprofit made from
licensing its name to companies carrying AARP-branded
products, such as credit cards and insurance policies.
UnitedHealth Group (NYSE: UNH), which sells
AARP-branded Medicare Advantage and Medigap coverage to
seniors, contributed 63% of that amount, according to
reports.
Republicans want to know whether AARP would get more money
from its branded Medigap policies, because it's expected that
cuts to Medicare Advantage will result in having seniors
switch from Medicare Advantage to cheaper Medigap coverage.
If that's true, Republicans say AARP may be supporting
health-care reform simply because it'll make more money.
Even so, does it matter? AARP is a nonprofit organization,
after all. If it's going to make more money by having the
legislation passed, then it'll obviously have more money to
support seniors and can save money in other areas. It's kind
of a cyclical argument.
And besides, there's a much simpler reason AARP supports
health-care reform.
Caught in a pickle-flavored doughnut hole
It's true that health-care reform isn't going to be
perfect for seniors. There's a good chance that Medicare
Advantage payments are going to get cut. Doing so will result
in less coverage or higher rates by the private insurers that
offer the plans.
But the cuts were coming whether a larger health-care
reform happened or not. The Medicare Advantage program, which
offers additional service above what Medicare provides, is an
easy target because it costs the government 14% more to cover
someone on it rather than somebody on traditional Medicare.
AARP had to pick its battles, and not everything about the
health-care bill is bad for seniors.
For instance, the bills making their way through Congress
contain a
dealnegotiated by AARP to get pharmaceutical companies
such as
Pfizer (NYSE: PFE) and
Merck (NYSE: MRK) to cover some of the
doughnut hole in the Medicare Part D prescription-drug
program.
Seniors currently have drug coverage up to a certain
dollar amount, but then they have to pay the full amount of
their drug costs -- the doughnut hole -- before catastrophic
drug benefits kicks in. This year, that hole is about $4,350
of out-of-pocket expenses. In addition to costing seniors
quite a bit of money, it leads to health deterioration, as
some seniors simply stop taking medications when the
first-level coverage runs out.
Pharmaceutical companies have pledged rebates of up to 50%
to cover costs while seniors are in the doughnut hole, but
only if comprehensive health-care reform passes. In other
words, the industry is willing to kick in, but only if
everyone else is, too. Continued... |